CELZ In the past 4 weeks we have seen a resurgence in our business with reorders from existing practices as well as greater interest from new practices. Much of the interest is coming from referrals from existing practices successfully treating patients. We expect this increase to continue and to grow in the 3rd quarter. FemCelz® Regenerative Stem Cell Procedure for Treatment of Female Sexual Dysfunction As described within our CaverStem® summary, FemCelz® was also impacted by COVID-19. We are continuing to expand our practice base and anticipate a positive incline in this business as well. OvaStemTM Regenerative Stem Cell Procedure for Treatment of Premature Ovarian Failure We are pleased to announce notification from the US Patent and Trademark Office that our Patent claims have been issued. The issued claims are broad and provide patent protection for the use of stem cells from multiple origins including autologous bone marrow derived stem cells and allogenic stem cells derived from sources such as amniotic fluid and cord blood. The broad claims provide the company significant flexibility as we shall pursue the Autologous method of treatment as CaverStem® and FemCelz®. We may also pursue the Allogenic method which would require Clinical Trials and FDA approval. It is our goal to seek out a joint venture partner to execute on the Allogenic model as significant time and resources would be required. AmnioStem™ and StemSpine® Updates will be released soon.
News 
Market Data 
Discover 
